Kenneth Rainin Foundation Awards $2.6 Million for Cutting-Edge IBD Research
02 oct. 2018 08h00 HE
|
Kenneth Rainin Foundation
Oakland, California, Oct. 02, 2018 (GLOBE NEWSWIRE) -- The Kenneth Rainin Foundation has awarded $2.6 million through its Innovator Awards program to improve the prediction and prevention of...
RedHill Biopharma Elaborates on Its Announced Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
01 août 2018 08h16 HE
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
Qu Biologics enrolls the first patient in new Phase 2 Crohn’s Disease clinical trial
25 juil. 2018 12h53 HE
|
Qu Biologics
VANCOUVER, British Columbia, July 25, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
RedHill Biopharma Announces Allowance of Two New RHB-104 Patents Ahead of Top-Line Phase III Results for Crohn’s Disease
02 juil. 2018 07h00 HE
|
RedHill Biopharma Ltd.
RedHill has received Notices of Allowance for two new patents covering RHB-104 in the U.S. and Europe which are expected to be valid until at least 2029, once granted Top-line results from the first...
Thetis Pharmaceuticals Receives $1.9 Million Fast-Track NIH Grant to Advance Novel Inflammatory Bowel Disease Drug Pipeline Toward Clinical Investigation
23 mai 2018 16h03 HE
|
Thetis Pharmaceuticals LLC
BRANFORD, Conn., May 23, 2018 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals, a biopharmaceutical company developing novel therapies for treatment of inflammatory bowel disease (IBD), today announced...
FDA & Industry Veteran Brian E. Harvey, MD, PhD, Joins Thetis Pharmaceuticals as Senior Medical Director
07 mai 2018 12h27 HE
|
Thetis Pharmaceuticals LLC
BRANFORD, Conn., May 07, 2018 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing first-in-class, immuno-resolving small molecule drugs to treat...
Qu Biologics Begins Phase 2 Clinical Trial in Crohn’s Disease
18 avr. 2018 16h16 HE
|
Qu Biologics
VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a Vancouver, Canada-based biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique...
Regentys Names Dr. John F. Howes Vice President of Clinical and Regulatory Affairs
09 janv. 2018 07h30 HE
|
Regentys
MIAMI LAKES, Fla., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Regentys (formerly Asana Medical, Inc.) (the “Company”), a regenerative medicine company developing a novel treatment for Ulcerative Colitis...
Thetis Pharmaceuticals Awarded $2.3 Million Fast-Track NIH Grant to Develop Immuno-Resolving Therapy for Inflammatory Bowel Disease
16 nov. 2017 12h35 HE
|
Thetis Pharmaceuticals LLC
BRANFORD, Conn., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals, a biopharmaceutical company developing “immuno-resolving” therapies for treatment of inflammatory bowel disease (IBD),...
RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease
09 nov. 2017 07h00 HE
|
RedHill Biopharma Ltd.
Top-line results are expected to be announced in mid-2018 The Phase III study evaluating RHB-104 for Crohn’s disease (MAP US study) is a randomized, double-blind, placebo-controlled study that is...